|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
956,580,000 |
Market
Cap: |
703.06(B) |
Last
Volume: |
4,591,951 |
Avg
Vol: |
3,291,238 |
52
Week Range: |
$423.21 - $792.28 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 720 |
Guru Rank Value : 1.4 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
656 |
Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
435,750 |
871,420 |
2,731,506 |
6,211,418 |
Total Sell Value |
$330,574,311 |
$608,633,217 |
$2,147,483,647 |
$2,147,483,647 |
Total People Sold |
2 |
2 |
5 |
6 |
Total Sell Transactions |
5 |
14 |
44 |
89 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Van Naarden Jacob |
EVP and CEO Loxo@Lilly |
|
2023-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,785 |
13,159 |
|
- |
|
White Anne E. |
EVP & Pres, Lilly Neuroscience |
|
2023-02-13 |
4 |
AS |
$346.47 |
$866,175 |
D/D |
(2,500) |
57,926 |
|
31% |
|
Hakim Anat |
EVP, GC & Secretary |
|
2023-02-10 |
4 |
A |
$345.12 |
$3,130,929 |
D/D |
9,072 |
22,189 |
|
- |
|
Dozier Eric |
EVP, HR & Diversity |
|
2023-02-10 |
4 |
A |
$345.12 |
$628,118 |
D/D |
1,820 |
5,920 |
|
- |
|
Skovronsky Daniel |
EVP, CS&MO & Pres., LRL |
|
2023-02-10 |
4 |
A |
$345.12 |
$6,346,067 |
D/D |
18,388 |
105,587 |
|
- |
|
Pusey Leigh Ann |
EVP, Corp. Affairs & Comm. |
|
2023-02-10 |
4 |
A |
$345.12 |
$1,270,387 |
D/D |
3,681 |
31,641 |
|
- |
|
White Anne E. |
EVP & Pres, Lilly Neuroscience |
|
2023-02-10 |
4 |
AS |
$342.76 |
$856,900 |
D/D |
(2,500) |
60,426 |
|
33% |
|
White Anne E. |
EVP & Pres, Lilly Neuroscience |
|
2023-02-10 |
4 |
A |
$345.12 |
$2,954,917 |
D/D |
8,562 |
62,926 |
|
- |
|
Weems Alonzo |
EVP, ERM & CECO |
|
2023-02-10 |
4 |
A |
$345.12 |
$835,881 |
D/D |
2,422 |
8,922 |
|
- |
|
Yuffa Ilya |
EVP & President, LLY Intl |
|
2023-02-10 |
4 |
A |
$345.12 |
$465,912 |
D/D |
1,350 |
12,974 |
|
- |
|
Mason Michael B |
EVP & Pres., Lilly Diabetes |
|
2023-02-10 |
4 |
A |
$345.12 |
$2,768,898 |
D/D |
8,023 |
39,284 |
|
- |
|
Zakrowski Donald A |
SVP, Finance, & CAO |
|
2023-02-10 |
4 |
A |
$345.12 |
$657,108 |
D/D |
1,904 |
7,178 |
|
- |
|
Norton Johna |
EVP, Global Quality |
|
2023-02-10 |
4 |
A |
$345.12 |
$865,216 |
D/D |
2,507 |
33,908 |
|
- |
|
Ricks David A |
President, Chair, and CEO |
|
2023-02-10 |
4 |
A |
$345.12 |
$19,398,505 |
D/D |
56,208 |
443,751 |
|
- |
|
Jonsson Patrik |
EVP&Pres, LLY Imm, LLY USA&CCO |
|
2023-02-10 |
4 |
A |
$345.12 |
$2,721,616 |
D/D |
7,886 |
42,941 |
|
- |
|
Ashkenazi Anat |
EVP & CFO |
|
2023-02-10 |
4 |
A |
$345.12 |
$2,309,888 |
D/D |
6,693 |
38,120 |
|
- |
|
Van Naarden Jacob |
EVP and CEO Loxo@Lilly |
|
2023-02-10 |
4 |
A |
$345.12 |
$830,704 |
D/D |
2,407 |
10,374 |
|
- |
|
Hernandez Edgardo |
EVP & Pres., Mfg. Operations |
|
2023-02-10 |
4 |
A |
$345.12 |
$1,796,004 |
D/D |
5,204 |
25,814 |
|
- |
|
Ricks David A |
President, Chair, and CEO |
|
2023-02-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,200 |
387,543 |
|
- |
|
Norton Johna |
EVP, Global Quality |
|
2023-02-01 |
4 |
D |
$344.15 |
$323,845 |
D/D |
(941) |
31,401 |
|
- |
|
Norton Johna |
EVP, Global Quality |
|
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,102 |
32,342 |
|
- |
|
Jonsson Patrik |
EVP&Pres, LLY Imm, LLY USA&CCO |
|
2023-02-01 |
4 |
D |
$344.15 |
$1,031,418 |
D/D |
(2,997) |
35,055 |
|
- |
|
Jonsson Patrik |
EVP&Pres, LLY Imm, LLY USA&CCO |
|
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,690 |
38,052 |
|
- |
|
Skovronsky Daniel |
EVP, CS&MO & Pres., LRL |
|
2023-02-01 |
4 |
D |
$344.15 |
$2,421,095 |
D/D |
(7,035) |
87,199 |
|
- |
|
Skovronsky Daniel |
EVP, CS&MO & Pres., LRL |
|
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,675 |
94,234 |
|
- |
|
306 Records found
|
|
Page 2 of 13 |
|
|